Imagen del editor

Peritoneal Carcinomatosis: Drugs and Diseases

Sugarbaker, Paul H. (Edited by)

0 valoraciones por Goodreads
ISBN 10: 1461285305 / ISBN 13: 9781461285304
Editorial: Springer, 2011
Nuevos Condición: Brand New Encuadernación de tapa blanda
Librería: Revaluation Books (Exeter, Reino Unido)

Librería en AbeBooks desde: 6 de enero de 2003

Cantidad: 2

Comprar nuevo
Precio recomendado: 399.00
Precio: EUR 387,79 Convertir moneda
Gastos de envío: EUR 6,80 De Reino Unido a Estados Unidos de America Destinos, gastos y plazos de envío
Añadir al carrito

Descripción

reprint edition. 288 pages. 10.00x7.01x0.68 inches. In Stock. N° de ref. de la librería x-1461285305

Hacer una pregunta a la librería

Detalles bibliográficos

Título: Peritoneal Carcinomatosis: Drugs and ...

Editorial: Springer

Año de publicación: 2011

Encuadernación: Paperback

Condición del libro:Brand New

Acerca de

Sinopsis:

Peritoneal carcinomatosis dominates the clinical picture of many patients with gastrointestinal, gynecological and urological cancers. For many of them its dev­ astating effects contribute directly to their death. Most clinicians consider peritoneal carcinomatosis an incurable metastatic disease and give palliative treatment, re­ stricted to limited surgery and systemic chemotherapy. Contrary to this view, Paul Sugarbaker and his collegues base their approach on the concept that peritoneal carcinomatosis represents regional tumor spread, similar in its impact on treatment and prognosis to that of lymph node metastases in other malignancies. This concept emphasises the value of regional tumor control, as a potentially curative measure. In this book the combination of aggressive cytoreduction and intraperitoneal chemotherapy to control peritoneal carcinomatosis is extensively explored. Basic to this approach is the observation that most cancer cells show only relative resistence against commonly available drugs, which can be overcome by a sufficient increase of drug concentrations in tumor tissue. After intraperitoneal delivery, drugs will reach high tissue concentrations in the superficial few cell layers, while plasma concentrations will remain below toxic levels. Patients with only limited residual tumor at the peritoneal surface after cytoreduction may therefore benefit from intraperitoneal chemotherapy.

"Sobre este título" puede pertenecer a otra edición de este libro.

Descripción de la librería

Ver la página web de la librería

Condiciones de venta:
Condiciones de envío:

Todos los libros de esta librería

Métodos de pago
aceptados por la librería

Visa Mastercard American Express Carte Bleue